Trial comparing treatments for Breast Neoplasms
Official title A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
ClinicalTrials.gov ID: NCT06312176
What this study is testing
What is Sacituzumab tirumotecan?
An investigational IV infusion medicine being studied for hormone receptor positive/HER2-negative breast cancer.
Also referred to as MK-2870.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether sacituzumab tirumotecan alone or with pembrolizumab can keep cancer from growing longer than doctors’ usual treatments.
- Who it's for
- You may be able to join if you have hormone‑positive, HER2‑negative breast cancer that cannot be removed and has spread or is advanced.
- What's involved
- You will receive either sacituzumab tirumotecan alone, sacituzumab tirumotecan with pembrolizumab, or a treatment chosen by your doctor. You will have regular visits for blood tests, scans, and doctor check‑ups to see how the cancer responds.
- Time commitment
- The study lasts about 12 months, with visits every few weeks for treatment and monitoring.
- Phase 3: a large, late-stage study
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative...
- Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer...
- Is a chemotherapy candidate
- Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization
- Has adequate organ function
You likely can't join if
- Has breast cancer amenable to treatment with curative intent
- Has experienced an early recurrence (\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line...
- Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications
- Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease
See the full eligibility criteria
- Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer
- Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor
- Is a chemotherapy candidate
- Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization
- Has adequate organ function
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Has breast cancer amenable to treatment with curative intent
- Has experienced an early recurrence (\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment
- Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications
- Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer
- Active autoimmune disease that has required systemic treatment in the past 2 years
- History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease
- Has an active infection requiring systemic therapy
The study team makes the final eligibility decision.
Where it is enrolling
- Chandler, Arizona, United States
- Gilbert, Arizona, United States
- Fullerton, California, United States
- Aurora, Colorado, United States
- Denver, Colorado, United States
- Stamford, Connecticut, United States
- Altamonte Springs, Florida, United States
- Orlando, Florida, United States
- Chicago, Illinois, United States
- Edgewood, Kentucky, United States
- Baton Rouge, Louisiana, United States
- Baltimore, Maryland, United States
- Silver Spring, Maryland, United States
- Boston, Massachusetts, United States
- Detroit, Michigan, United States
- Kansas City, Missouri, United States
- St Louis, Missouri, United States
- Brooklyn, New York, United States
- Mineola, New York, United States
- New York, New York, United States
+ 140 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Chandler, Arizona, United States; Gilbert, Arizona, United States; Fullerton, California, United States; Aurora, Colorado, United States; Denver, Colorado, United States; Stamford, Connecticut, United States and 154 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.